CoDiagnostics Secures Patent for Co-Dx PCR Technology Amidst Market Innovations

Co-Diagnostics Secures Patented Technology for Innovative PCR Testing

CoDiagnostics, Inc. has achieved a significant milestone with the granting of its first patent for the Co-Dx PCR platform by the Australian Patent Office. The patent, officially recognized as AU2022270084A1, safeguards the design and operation of the Co-Dx PCR Pro™ instrument and its testing cups, which are pivotal for conducting polymerase chain reaction (PCR) tests outside traditional laboratory environments. Filed in May 2022 and granted in June 2023, this intellectual property strengthens Co-Diagnostics' position in the burgeoning molecular diagnostics sector, particularly as demand for rapid and accurate tests continues to rise globally.

CEO Dwight Egan emphasizes the importance of this patent in securing global protection for Co-Diagnostics' technology, which is essential for expanding the Co-Dx PCR platform's applications. As Australia faces a record-breaking flu season, the timing of this patent acquisition proves strategic, as it bolsters the commercial potential of the Co-Dx PCR Flu A/B, COVID, and RSV multiplex test currently undergoing clinical performance assessments. The Co-Dx PCR platform is engineered to deliver gold-standard PCR accuracy, making it an appealing option for decentralized testing in various settings, including clinics and remote healthcare facilities.

Utilizing Co-Diagnostics' proprietary Co-Primers® technology, the Co-Dx PCR platform aims to enhance the speed and sensitivity of molecular diagnostics for a wide range of infectious diseases. Although the platform shows promise, it remains subject to review by the FDA and other regulatory bodies before it can be made available for commercial sale. As the company moves forward, its commitment to making accurate PCR testing accessible in critical areas where it is needed most remains evident, positioning Co-Diagnostics as a key player in the molecular diagnostics landscape.

In addition to this patent milestone, Co-Diagnostics is also preparing for a reverse stock split at a 1-for-30 ratio, effective January 2, 2026. This move, approved by stockholders, aims to help the company meet the minimum bid price requirements for continued listing on the Nasdaq Capital Market. While the focus remains on the advancements in molecular diagnostics, this financial maneuver reflects the company’s ongoing efforts to maintain its market presence and ensure operational viability.

Overall, the recent developments highlight Co-Diagnostics' commitment to innovation in molecular diagnostics, reinforcing its position in a critical industry that plays a vital role in public health, particularly in light of increasing global health challenges.